Currently, the intermittent systemic administration of hPTH (1–34) is utilized to treat senile osteoporosis,21, 22 osteoporosis secondary to prolonged glucocorticoid administration,23, 24, 25 and bisphosphonate‐associated osteonecrosis of the jaw.26, 27, 28, 29 Based on prior literature establishing that T2DM patients have both an increased risk of fracture30, 31, 32, 33, 34 and decreased PTH levels,19, 35, 36 it was determined practical to utilize hPTH (1–34) in the treatment of bone fractures secondary to T2DM. This evidence concerns the gene PTH and osteoporosis.